Task Force for Combating Antibiotic-Resistant Bacteria (CARB)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, ASPR
|
NIAID
|
2014
|
|
Taxonomics Methods Using DNA
|
Research Initiative
|
FDA
|
NLM
|
|
|
The Biology of HIV Infections
|
Research Initiative
|
FDA
|
NIAID
|
|
|
The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM)
|
Research Initiative
|
CDC, FDA
|
NHGRI, NHLBI
|
2010
|
|
The Impact of Tobacco Use on Oral Health and the Oral Microbiome
|
Research Initiative
|
CDC, FDA
|
|
2012
|
|
The Medical Devices Epidemiology Network (MDEpiNet) TMJ RoundTable (MDEpiNet TMJ RoundTable)
|
Meeting/ Workshop
|
AHRQ, FDA
|
|
2016
|
|
The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ATSDR
|
OD/ OSP
|
2001
|
|
The NIH Helping to End Addiction Long Term (HEAL) Initiative
|
Research Initiative
|
AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA
|
NCATS, NCCIH, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDDK, NIMH, NINDS, OD/ OSP, OD/ DPCPSI/ OBSSR
|
2018
|
|
The President's Task Force on Environmental Health risks and Safety risks to children; Asthma Disparities working group
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, IHS
|
NIAID, NICHD, NIMHD, NINR
|
2012
|
|
The Role of the Scavenger Receptor B Family Proteins (SR-BI, SR-BII and CD36) in Infection and Sepsis
|
Research Initiative
|
FDA
|
CC
|
|
|
Therapies for patients with rare tumors and genetic tumor predisposition
|
Research Initiative
|
FDA
|
NCI
|
|
|
Tobacco and Nicotine Research Interest Group (TANRIG)
|
Committee, Advisory Group, or Work Group
|
CDC, SAMHSA, FDA, CMS
|
FIC, NCI, NEI, NHGRI, CSR, NCCIH, NIAMS, NIMH
|
2003
|
|
Tobacco Product Disease Risks
|
Research Initiative
|
FDA
|
|
2016
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIEHS, OD/ OER
|
2012
|
|
Tobacco Use Supplement to Current Population Survey (TUS-CPS)
|
Health Survey
|
CDC, FDA
|
NIMHD
|
1992
|
|
Toxicology in the 21st Century (Tox 21)
|
Resource Development
|
FDA
|
NCATS, NIEHS
|
2008
|
|
Toxicology in the 21st Century Federal Consortium: NCATS Interagency Agreement, ES-7020-01, Year 11 (Tox21)
|
Research Initiative
|
FDA
|
NIEHS, NCATS
|
2007
|
|
Toxicology in the 21st Century Program (Tox21) - Computational Toxicology
|
Research Initiative
|
FDA
|
NCATS
|
|
|
Toxicology in the 21st Century Program (Tox21) - Systems Toxicology
|
Research Initiative
|
FDA
|
NCATS
|
|
|
Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2015
|
|
Toxins Assessment Working Group
|
Committee, Advisory Group, or Work Group
|
ASPR, CDC, FDA
|
NIAID
|
2019
|
|
Tracking Resistance and Coronavirus Evolution (TRACE)
|
Research Initiative
|
ASPR, CDC, FDA
|
NCATS, NIAID
|
2021
|
|
Trans-Agency (Medical) Imaging Phantom (TAIP) Workgroup
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIBIB
|
2021
|
|
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ASPR
|
NIAID
|
2009
|
|
Trans-HHS program for Multi-System Inflammatory Syndrome in Children (MIS-C) and pediatric SARS-CoV-2 (CARING)
|
Research Initiative
|
CDC, FDA, OASH
|
|
2020
|
|
|